18F-FDG PET/CT evaluation of Ceritinib therapy in metastatic ALK-positive non-small cell lung cancer

Sébastien Dejust David Morland 1, 2, 3 Fabre Guillaume Alain Prévost Dimitri Papathanassiou 1, 2, 3
1 Département de Médecine Nucléaire, Institut Jean Godinot
2 Laboratoire de Biophysique, UFR de Médecine
3 CRESTIC - Centre de Recherche en Sciences et Technologies de l'Information et de la Communication - EA 3804
Abstract : Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancers (NSCLC) account for 3% to 7% of all NSCLC and require a standard treatment by crizotinib. However, crizotinib resistance is frequent within the first 12 months of treatment. Ceritinib is a novel tyrosine kinase inhibitor of ALK recently introduced in France for metastatic or locally advanced crizotinib-resistant ALK NSCLC. We report the first use of ceritinib in our institution with a spectacular tumoral response after only 3 months of treatment. This case demonstrates the major role of F-FDG PET/CT for monitoring the effectiveness of this new treatment.
Document type :
Journal articles
Complete list of metadatas
https://hal.univ-reims.fr/hal-01822370
Contributor : Nicolas Passat <>
Submitted on : Monday, June 25, 2018 - 8:55:29 AM
Last modification on : Friday, October 25, 2019 - 1:12:30 PM

Identifiers

Collections

URCA | CRESTIC

Citation

Sébastien Dejust, David Morland, Fabre Guillaume, Alain Prévost, Dimitri Papathanassiou. 18F-FDG PET/CT evaluation of Ceritinib therapy in metastatic ALK-positive non-small cell lung cancer. Clinical Nuclear Medicine, Lippincott, Williams & Wilkins, 2016, 41 (11), pp.879-880. ⟨10.1097/RLU.0000000000001361⟩. ⟨hal-01822370⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

47

 

HAL-contact@univ-reims.fr